Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders Post published:April 19, 2023 Post category:Press Release
Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia Post published:March 27, 2023 Post category:Press Release
Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia Post published:March 15, 2023 Post category:Press Release
Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’s Post published:February 13, 2023 Post category:Press Release
Silo Pharma Announces Expansion of Intellectual Property Portfolio Post published:February 2, 2023 Post category:Press Release
Silo Pharma Announces Stock Repurchase Program Post published:January 31, 2023 Post category:Press Release
Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation Post published:January 13, 2023 Post category:Press Release
Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine Post published:December 1, 2022 Post category:Press Release
Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue Post published:November 29, 2022 Post category:Press Release
Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference Post published:October 26, 2022 Post category:Press Release